Expressions of P-gp, ToPo II α, GST-π and c-erbB2 in endometrial cancer and their significance / 肿瘤

Objective: To investigate the expressions of P-glycoprotein (P-gp), topoisomerase II alpha (ToPo II α), glutathione-S-transferase-pi (GST-π), and oncogene c-erbB2 in endometrial cancer and their significance. Methods: Immunohistochemistry SP method was used to determine the expressions of P-gp, ToPo II α, GST-π and c-erbB2 in 127 tumor samples from patients with endometrial cancer. Results: Among 127 tumor samples from patients with endometrial cancer, the positive expression rates of P-gp, ToPo II α, GST-π and c-erbB2 were 63.0%, 44.9%, 70.1%, and 47.2%, respectively. The co-expression rate of P-gp and GST-π was 50.7%. The expression levels of P-gp, GST-π and c-erbB2 in poor differentiation endometrial cancer were significantly higher than those in well/moderate differentiation endometrial cancer (P < 0.05). While the expression level of ToPo II α in well/moderate differentiation endometrial cancer was significantly higher than that in poor differentiation endometrial cancer (P < 0.05). Univariate analysis indicated that the expression of P-gp, GST-π and c-erbB2 were associated with the survival time and poor prognosis of endometrial cancer patients. COX regression analysis suggested that the expression of P-gp and co-expression of P-gp and GST-π correlated with the survival rate of patients. Over-expression of ToPo II α tended to have protective effects on patients. Conclusion: Multidrug resistance-associated protein (MRP), GST-π, Topo II α, and lung resistance protein (LRP) plays important roles in the multidrug resistance(MDR) of tumor chemotherapy. Combined effects of the four multiple factors, P-gp, ToPo II α, GST-π and c-erbB2 were the main action mechanism for the MDR of endometrial cancer. It has an important guiding significance for predicting the prognosis and making rational chemotherapeutic regimens for patients with endometrial cancer.

Clinical efficacy of CT-guided implantation of iodine 125 seeds combined with intra-arterial perfusion of gemcitabine plus 5-fluorouracil on pancreatic cancer / 肿瘤

Objectives: To evaluate the safety and efficacy of CT-guided iodine 125 seed implantation combined with gemcitabine and 5-fluorouracil (5-FU)-based intra-arterial perfusion in the treatment of patients with advanced pancreatic cancer. Methods: A total of 16 patients with advanced unresectable pancreatic cancer underwent CT-guided iodine implantation combined with gemcitabine plus 5-FU-based intra-arterial perfusion. One week after implantation of iodine 125 seeds, all the patients received concurrent intra-arterial infusion of gemcitabine and 5-FU, which was repeated for 3 to 4 cycles. Three patients complicated with liver metastasis were given additional arterial embolization concurrently. Survival period, pain-relieving period, and adverse reaction of patients were observed. Results: All the patients were followed up for 2-25 months. CT scan found that there were 2 cases with complete response, 9 cases with partial response, 3 cases with stable disease, and 2 cases with progressive disease after 2 months of follow-up. The overall effective rate (CR + PR) was 68.8%. The median survival period for all enrolled patients was 11 months. It was 15 months for patients at stage II + III and 9 months for those at stage IV. No serious complications including gastrointestinal bleeding, pancreatitis, pancreatic fistula and radiation colitis were observed. Conclusion: CT-guided iodine 125 seed implantation combined with gemcitabine and 5-fluorouracil (5-FU)-based intra-arterial perfusion has better palliative pain-relieving effects. It has safe and effective effects in short terms and causes less complications in the treatment of advanced pancreatic cancer patients.

Dipeptidyl peptidase IV gene expression in ovarian carcinoma cell lines with various maligant behaviour / 中国医学科学院学报

<p><b>OBJECTIVE</b>To study the relationship between the expression of dipeptidyl peptidase IV (DPP IV) gene and malignant behavior of cells of ovarian carcinoma.</p><p><b>METHODS</b>The differences of the malignant behavior of A2780, SKOV-3, HO-8910 and HO-8910PM cell lines were examined by drawing cell proliferative curves, adhesive test, assay of incursion and chemotaxis. The expression of DPP IV among the cell lines and its relationship with the malignant behavior of ovarian carcinoma cell were detected by techniques of DPP IV activity assay, cytometry and reverse transcription polymerase chain reaction.</p><p><b>RESULTS</b>Among all cell lines, the ability of proliferation, adhesion, incursion and chemotaxis of HO-8910PM were the highest, while those of A2780 were the lowest. The transcription of mRNA in A2780, SKOV-3, HO-8910 and HO-8910PM cell lines were 0.7512 +/- 0.0012, 0.5596 +/- 0.0015, 0.3369 +/- 0.0009, and 0.2777 +/- 0.0006, respectively. The activity of DPP IV were 0.79 +/- 0.02, 0.64 +/- 0.03, 0.21 +/- 0.02, and 0.18 +/- 0.01, respectively; and the protein expression of DPP IV gene were 657.83 +/- 1.14, 538.53 +/- 5.29, 130.50 +/- 1.46, and 33.14 +/- 0.47, respectively, as assayed by cytometry. The correlation coefficients of the transcription of DPP IV gene and the adhesive, incursive and migratory ability of ovarian carcinoma cells were -0.987, -0.983, and -0.991, respectively; the correlation coefficients of the expression of DPP IV and those ability of cells were -0.959, -0.988, and -0.968; the correlation coefficients of the activity of DPP IV and those ability of cells were -0.952, -0.868, and -0.983.</p><p><b>CONCLUSION</b>There is a negative correlation between the expression of DPP IV gene and the adhesive and incursive capability of cells of ovarian carcinoma.</p>

Treatment of AIDS patients with Chinese medicinal herbs qudu zengning capsule / 中华实验和临床病毒学杂志

<p><b>OBJECTIVE</b>To evaluate the therapeutic effect of QuDu ZengNing Capsule on AIDS.</p><p><b>METHODS</b>QuDu ZengNing Capsule is a capsule containing extract from 4 Chinese medicinal herbs. Totally 1,000 AIDS patients were treated, among them 60 patients were clinically observed weekly. Blood routine tests, liver, heart and kidney function, X-ray, CD4, CD8 cells were examined before and after treatment at 1, 3, 6 month. The patients were treated with 4 capsules t.i.d for 6 months.</p><p><b>RESULTS</b>The symptoms were improved in most of the patients, the CD4 cells increased from 115.0 to 295.2/ul and the viral load (RNA copies/ml) in most patients reduced markedly or maintained at the same level.</p><p><b>CONCLUSION</b>These data indicated that QuDu ZengNing Capsule was effective for treatment of AIDS patients.</p>